7 December 2021 - NICE is unable to make a recommendation on the use of olaparib (Lynparza) on the NHS for the maintenance treatment of patients with BRCA mutation positive metastatic pancreatic cancer after platinum-based chemotherapy.

This is because AstraZeneca did not provide an evidence submission.

There seems to have been an extra-ordinary number of terminated appraisals this year. We will examine this in more detail in a future issue of MAESTrO Daily.

Read NICE technology appraisal for olaparib